Pharming Group N.V. today announced it has received European Medicines Agency (EMA) approval of a Type II Variation for a new production facility for its lead product, RUCONEST®.

Pharming Group N.V. announces today the placement of €125 million of senior unsecured convertible bonds due 2025 (the “Bonds”). The offer was fully subscribed. The Bonds were offered via an accelerated book building process through a private placement only to institutional investors outside the United States of America, Australia, South Africa, and Japan.

Pharming Group N.V. today announces the launch of an offering (the “Offering”) of approximately €125 million of senior unsecured convertible bonds due 2025 (the “Bonds”). The net proceeds of the issue of the Bonds will be used to redeem the approximately US$ 56 million loan with Orbimed Advisors in full, thereby reducing the Company’s financing costs and extending its debt maturity through the period to approval of most of the Company’s existing pipeline. The balance of the net proceeds will be used to support capital expenditure in relation to the expansion of the commercialization and manufacturing infrastructure of the Company, and serve as funding for the launch of Pharming’s recently acquired leniolisib product and for additional acquisitions/in-licensing opportunities.

Pharming Group N.V. today announced it has entered into a definitive agreement with Swedish Orphan Biovitrum AB (publ) (“Sobi”) to reacquire the commercial rights to Pharming’s product, RUCONEST®, in all remaining territories, which includes all remaining EU markets. Under the agreement, the license is being terminated with effect from 1 January 2020 in all 36 countries with a smooth handover planned in the countries where Sobi has sales activities. Pharming will pay Sobi €7.5 million in two tranches.

Pharming Group N.V. presents at the first "PharmingForum" Day on the 26th of October 2019 in Gilze en Rijen. Pharming was honored to present to the forum members alongside our esteemed colleague Professor Michael Osthoff, M.D. from Basel University.

Pharming Group N.V. presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2019.

CSL Behring and Pharming have mutually agreed that CSL will dismiss Pharming from the case against Dr. Chiao.

Pharming Group N.V. today confirmed it has been included in an injunction in the US obtained by CSL Behring, a subsidiary of CSL Limited of Australia (“CSL”), to prevent possible transmission of proprietary documents and data to Pharming which CSL claims have been removed from its systems by Dr Joseph Chiao, who was hired recently by Pharming to be a medical director.

CEO of Pharming Sijmen de Vries presented at the 21st Annual Global Life Science Investment Conference on the 9th of September in New York City.